Literature DB >> 33230533

Extracorporeal life support rewarming rate is associated with survival with good neurological outcome in accidental hypothermia.

Richard Saczkowski1, Nick Kuzak2,3,4, Brian Grunau5, Costas Schulze1,6.   

Abstract

OBJECTIVES: Favourable outcomes have been demonstrated after extracorporeal life support (ECLS) facilitated rewarming for severe accidental hypothermia. The clinical impact of varying rewarming rates however is unclear. We sought to quantify the change in the probability of good neurological outcome with ECLS rewarming rate and identify the optimal rewarming rate threshold.
METHODS: We performed a secondary analysis of the International ACcidental Hypothermia Extracorporeal Life Support Collaborators, an individual patient data data set (n = 658) for ECLS-assisted rewarming for accidental hypothermia. The independent variable of interest was rewarming rate. The primary outcome was survival with good neurological status. We applied an adjusted marginal effects model to quantify the probability of good neurological outcome over clinically observed rewarming rates. We examined strata defined by sex, initial potassium level and history of asphyxiation.
RESULTS: Of 658 cases, the median age and initial core temperature were 36 years (22-55) and 24.5°C (22.1-26.2) respectively; 190 (29%) were female, and 547 (83%) had a non-perfusing initial cardiac rhythm. The mean rewarming rate was 7.0°C/h. The median ECLS duration was 5.8 h (range: 0.5-158 h). The overall survival was 46% (n = 303/658), and good neurological outcome was 40% (n = 265/658). The median intensive care unit and hospital length of stay was 5 days (range: 1-35 days) and 18 days (range: 1-106 days), respectively. Marginal effects analysis demonstrated a 1.9% decrease in the probability of survival with good neurological outcome for each 1°C/h increase in rewarming. Across the reported range of rewarming rates (0.05-30.8°C/h), the probability of good neurological outcome declined from 49.6% to 4.1% for an average patient. The relationship was similar within various subgroups. The optimal cut-off threshold for the rate of rewarming to distinguish between a good and poor neurological outcome was ≤5.0°C/h.
CONCLUSIONS: Among cases with severe accidental hypothermia treated with ECLS, slower rewarming rates are associated with improved survival with good neurological outcomes. Slow rewarming, at rates ≤5.0°C/h, may improve clinical outcomes.
© The Author(s) 2020. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Accidental hypothermia; ECLS; ECMO; IPD; Meta-analysis; Rewarming rate

Year:  2021        PMID: 33230533     DOI: 10.1093/ejcts/ezaa385

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  4 in total

Review 1.  Accidental Hypothermia: 2021 Update.

Authors:  Peter Paal; Mathieu Pasquier; Tomasz Darocha; Raimund Lechner; Sylweriusz Kosinski; Bernd Wallner; Ken Zafren; Hermann Brugger
Journal:  Int J Environ Res Public Health       Date:  2022-01-03       Impact factor: 3.390

2.  Intensive care with extracorporeal membrane oxygenation rewarming in accident severe hypothermia (ICE-CRASH) study: a protocol for a multicentre prospective, observational study in Japan.

Authors:  Shuhei Takauji; Mineji Hayakawa
Journal:  BMJ Open       Date:  2021-10-28       Impact factor: 2.692

3.  Functional recovery after accidental deep hypothermic cardiac arrest: Comparison of different cardiopulmonary bypass rewarming strategies.

Authors:  Ole Magnus Filseth; Timofei Kondratiev; Gary C Sieck; Torkjel Tveita
Journal:  Front Physiol       Date:  2022-09-05       Impact factor: 4.755

Review 4.  Extracorporeal Life Support in Accidental Hypothermia with Cardiac Arrest-A Narrative Review.

Authors:  Justyna Swol; Tomasz Darocha; Peter Paal; Hermann Brugger; Paweł Podsiadło; Sylweriusz Kosiński; Mateusz Puślecki; Marcin Ligowski; Mathieu Pasquier
Journal:  ASAIO J       Date:  2022-02-01       Impact factor: 2.872

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.